{
    "clinical_study": {
        "@rank": "78829", 
        "arm_group": {
            "arm_group_label": "ISIS-SMNRx", 
            "arm_group_type": "Experimental", 
            "description": "Dose Level 1"
        }, 
        "brief_summary": {
            "textblock": "This study will test the safety and tolerability of ISIS-SMNRx administered into the spinal\n      fluid as a single injection in patients with Spinal Muscular Atrophy, who previously\n      participated in ISIS 396443-CS1"
        }, 
        "brief_title": "An Open-label Safety and Tolerability Study of ISIS SMNRx in Patients With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Spinal Muscular Atrophy", 
        "condition_browse": {
            "mesh_term": [
                "Muscular Atrophy", 
                "Muscular Atrophy, Spinal", 
                "Atrophy"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will test the safety, tolerability, and pharmacokinetics of a single dose of\n      ISIS-SMNRx administered as a single intrathecal injection. The single dose will be studied\n      in patients who previously participated in ISIS 396443-CS1, and all patients will receive\n      active drug."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical signs attributable to Spinal Muscular Atrophy\n\n          -  Satisfactory completion of dosing and all study visits in ISIS 396443-CS1 with an\n             acceptable safety profile, per Investigator judgement.\n\n          -  Able to complete all study procedures, measurements and visits and parent/patient has\n             adequately supportive psychosocial circumstances, in the opinion of the investigator\n\n          -  Estimated life expectancy > 2 years from Screening\n\n          -  Meets age-appropriate institutional criteria for use of anesthesia/sedation, if use\n             is planned for study procedure\n\n        Exclusion Criteria:\n\n          -  Have any  new or worsening of existing condition which in the opinion of the\n             Investigator would make the subject unsuitable for enrollment, or could interfere\n             with the subject participating in or completing the study.\n\n          -  Dosing in ISIS 396443-CS1 within 270 days (9 months) of screening, or longer ago than\n             450 days (15 months)\n\n          -  Dosing in ISIS 396443-CS2\n\n          -  Hospitalization for surgery (i.e. scoliosis surgery) or pulmonary event within 2\n             months of screening or planned during the duration of the study\n\n          -  Presence of an untreated or inadequately treated active infection requiring systemic\n             antiviral or antimicrobial therapy any time during the screening period\n\n          -  Clinically significant abnormalities in hematology or clinical chemistry parameters\n\n          -  Treatment with investigational drug, biological agent, or device within 1-month of\n             Screening or 5 half-lives of study agent, whichever is longer. Treatment with\n             valproate or hydroxyurea within 1 months of screening. Any history of gene therapy or\n             cell transplantation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "15 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01780246", 
            "org_study_id": "ISIS 396443-CS10"
        }, 
        "intervention": {
            "arm_group_label": "ISIS-SMNRx", 
            "description": "Single intrathecal injection", 
            "intervention_name": "ISIS-SMNRx", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Spinal Muscular Atrophy", 
            "SMA", 
            "SMN", 
            "SMNRx", 
            "ISIS-SMNRx", 
            "ISIS 396443"
        ], 
        "lastchanged_date": "September 17, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Boston Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75207"
                    }, 
                    "name": "UT Southwestern Medical Center - Children's Medical Center Dallas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84132"
                    }, 
                    "name": "University of Utah School of Medicine"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Study to Assess the Safety and Tolerability of a Single Intrathecal Dose of ISIS 396443 in Patients With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Participants will be followed for the duration of the study; an expected 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01780246"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "the maximal observed plasma drug concentration (Cmax)\nthe time to reach Cmax in plasma (Tmax)\nthe area under the plasma concentrations time curve from the time of the intrathecal dose to the last collected sample (6 hours after dosing)", 
            "measure": "Plasma Pharmacokinetics (See clarification.)", 
            "safety_issue": "No", 
            "time_frame": "Plasma at 1, 2, 4 and 6 hours after dosing"
        }, 
        "source": "Isis Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}